A Sionna Therapeutics (SION) Insider Sold 33,000 Shares for $1.5 Million

1 week ago 10

Cory Renauer, The Motley Fool

Sat, January 3, 2026 astatine 1:55 PM CST 5 min read

33,356 shares sold for a transaction worth of $1,486,009.80 connected Dec. 24, 2025.
Reducing full indirect ownership to 3,561,655 shares.
All shares were disposed via indirect ownership done OrbiMed Private Investments VIII, LP; nary nonstop holdings earlier oregon aft the sale.
Sell size matched the median for caller disposals, and came arsenic disposable capableness declined to adjacent zero pursuing a bid of ample transactions successful 2025.
These 10 stocks could mint the adjacent question of millionaires ›

Advisors LLC Orbimed, serving arsenic Director astatine Sionna Therapeutics (NASDAQ:SION), disposed of 33,356 shares successful an open-market merchantability valued astatine $1,486,009.80 connected Dec. 24, 2025, via indirect holdings attributed to OrbiMed Private Investments VIII, LP; spot SEC Form 4 filing.

Metric

Value

Shares sold (indirect)	33,356
Transaction value	$1.5 million
Post-transaction shares (direct)
Post-transaction shares (indirect)	3,561,655

What information of Advisors LLC Orbimed's Sionna Therapeutics presumption was impacted by this sale?
This transaction represented 0.93% of Advisors LLC Orbimed's indirect holdings, with each shares sold from the OrbiMed Private Investments VIII, LP entity and nary nonstop holdings affected.
How does the commercialized size comparison to Advisors LLC Orbimed's caller disposition pattern?
The 33,356-share merchantability is successful enactment with the median size of caller open-market income (also 33,356 shares), suggesting continued usage of structured, incremental artifact income arsenic holdings attack exhaustion.
Was determination immoderate nonstop ownership progressive successful this transaction?
No; each shares were held and disposed indirectly via OrbiMed Private Investments VIII, LP, with nonstop ownership remaining astatine zero some earlier and aft the transaction.
Does this transaction bespeak discretionary selling oregon is it chiefly a relation of disposable capacity?
The size and timing of the merchantability were dictated by remaining stock capacity, arsenic Advisors LLC Orbimed's indirect holdings person declined sharply successful 2025, leaving small country for further large-scale disposals.

Metric

Value

Price (as of marketplace adjacent 12/24/25)	$44.55
Market capitalization	$1.75 billion
Net income (TTM)	($70.7 million)
1-year terms change	56.80%

* 1-year terms alteration calculated utilizing Dec. 24, 2025 arsenic the notation date.

Develops biopharmaceutical therapies targeting cystic fibrosis by aiming to normalize the relation of the cystic fibrosis transmembrane conductance regulator (CFTR) protein.
Targets patients with cystic fibrosis and healthcare providers specializing successful uncommon familial diseases arsenic the superior lawsuit base.